Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

TIVC vs GKOS vs NVCR vs HOLX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TIVC
Tivic Health Systems, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$3M
5Y Perf.-100.0%
GKOS
Glaukos Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$7.85B
5Y Perf.+233.9%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-83.8%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+1.2%

TIVC vs GKOS vs NVCR vs HOLX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TIVC logoTIVC
GKOS logoGKOS
NVCR logoNVCR
HOLX logoHOLX
IndustryMedical - DevicesMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$3M$7.85B$1.92B$16.97B
Revenue (TTM)$482K$551M$674M$4.13B
Net Income (TTM)$-8M$-189M$-173M$544M
Gross Margin-58.1%78.1%75.2%52.8%
Operating Margin-15.5%-15.6%-27.2%17.5%
Forward P/E17.2x
Total Debt$0.00$140M$290M$2.63B
Cash & Equiv.$2M$91M$103M$1.96B

TIVC vs GKOS vs NVCR vs HOLXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TIVC
GKOS
NVCR
HOLX
StockNov 21May 26Return
Tivic Health System… (TIVC)1000.0-100.0%
Glaukos Corporation (GKOS)100333.9+233.9%
NovoCure Limited (NVCR)10016.2-83.8%
Hologic, Inc. (HOLX)100101.2+1.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: TIVC vs GKOS vs NVCR vs HOLX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Glaukos Corporation is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
TIVC
Tivic Health Systems, Inc.
The Specific-Use Pick

TIVC plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
GKOS
Glaukos Corporation
The Growth Play

GKOS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 32.3%, EPS growth -18.4%, 3Y rev CAGR 21.5%
  • 457.1% 10Y total return vs HOLX's 124.3%
  • Lower volatility, beta 1.20, Low D/E 21.3%, current ratio 4.69x
  • 32.3% revenue growth vs TIVC's -33.7%
Best for: growth exposure and long-term compounding
NVCR
NovoCure Limited
The Secondary Option

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
HOLX
Hologic, Inc.
The Income Pick

HOLX carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • beta 0.41
  • Beta 0.41, current ratio 3.75x
  • 13.2% margin vs TIVC's -15.6%
  • Beta 0.41 vs NVCR's 2.20, lower leverage
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthGKOS logoGKOS32.3% revenue growth vs TIVC's -33.7%
Quality / MarginsHOLX logoHOLX13.2% margin vs TIVC's -15.6%
Stability / SafetyHOLX logoHOLXBeta 0.41 vs NVCR's 2.20, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)GKOS logoGKOS+52.0% vs TIVC's -76.0%
Efficiency (ROA)HOLX logoHOLX6.1% ROA vs TIVC's -173.3%, ROIC 9.4% vs -7.8%

TIVC vs GKOS vs NVCR vs HOLX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TIVCTivic Health Systems, Inc.
FY 2024
Shipping and Handling
100.0%$1,000
GKOSGlaukos Corporation
FY 2019
Glaucoma
97.5%$231M
Corneal Health
2.5%$6M
NVCRNovoCure Limited

Segment breakdown not available.

HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M

TIVC vs GKOS vs NVCR vs HOLX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHOLXLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

HOLX leads this category, winning 3 of 6 comparable metrics.

HOLX is the larger business by revenue, generating $4.1B annually — 8561.0x TIVC's $482,000. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to TIVC's -15.6%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTIVC logoTIVCTivic Health Syst…GKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
RevenueTrailing 12 months$482,000$551M$674M$4.1B
EBITDAEarnings before interest/tax-$7M-$40M-$165M$974M
Net IncomeAfter-tax profit-$8M-$189M-$173M$544M
Free Cash FlowCash after capex-$6M-$18M-$48M$1000M
Gross MarginGross profit ÷ Revenue-58.1%+78.1%+75.2%+52.8%
Operating MarginEBIT ÷ Revenue-15.5%-15.6%-27.2%+17.5%
Net MarginNet income ÷ Revenue-15.6%-34.3%-25.7%+13.2%
FCF MarginFCF ÷ Revenue-12.7%-3.4%-7.1%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year+15.9%+41.2%+12.3%+2.5%
EPS Growth (YoY)Latest quarter vs prior year+49.9%-6.3%-100.0%-9.2%
HOLX leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — GKOS and NVCR and HOLX each lead in 1 of 3 comparable metrics.
MetricTIVC logoTIVCTivic Health Syst…GKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Market CapShares × price$3M$7.9B$1.9B$17.0B
Enterprise ValueMkt cap + debt − cash$599,551$7.9B$2.1B$17.6B
Trailing P/EPrice ÷ TTM EPS-0.05x-40.90x-13.80x30.53x
Forward P/EPrice ÷ next-FY EPS est.17.21x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.39x
Price / SalesMarket cap ÷ Revenue3.34x15.47x2.92x4.14x
Price / BookPrice ÷ Book value/share116.77x11.69x5.51x3.43x
Price / FCFMarket cap ÷ FCF18.44x
Evenly matched — GKOS and NVCR and HOLX each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

HOLX leads this category, winning 6 of 9 comparable metrics.

HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-2 for TIVC. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs GKOS's 3/9, reflecting strong financial health.

MetricTIVC logoTIVCTivic Health Syst…GKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
ROE (TTM)Return on equity-2.0%-26.5%-50.8%+11.0%
ROA (TTM)Return on assets-173.3%-20.1%-16.5%+6.1%
ROICReturn on invested capital-7.8%-9.2%-16.4%+9.4%
ROCEReturn on capital employed-180.0%-10.3%-28.9%+8.8%
Piotroski ScoreFundamental quality 0–93357
Debt / EquityFinancial leverage0.21x0.85x0.52x
Net DebtTotal debt minus cash-$2M$49M$187M$667M
Cash & Equiv.Liquid assets$2M$91M$103M$2.0B
Total DebtShort + long-term debt$0$140M$290M$2.6B
Interest CoverageEBIT ÷ Interest expense-18.69x-96.80x8.00x
HOLX leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GKOS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in GKOS five years ago would be worth $16,155 today (with dividends reinvested), compared to $1 for TIVC. Over the past 12 months, GKOS leads with a +52.0% total return vs TIVC's -76.0%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.7% vs TIVC's -83.3% — a key indicator of consistent wealth creation.

MetricTIVC logoTIVCTivic Health Syst…GKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
YTD ReturnYear-to-date-27.5%+21.2%+28.3%+1.9%
1-Year ReturnPast 12 months-76.0%+52.0%+1.1%+37.1%
3-Year ReturnCumulative with dividends-99.5%+128.7%-75.7%-8.5%
5-Year ReturnCumulative with dividends-100.0%+61.5%-91.3%+15.8%
10-Year ReturnCumulative with dividends-100.0%+457.1%+30.3%+124.3%
CAGR (3Y)Annualised 3-year return-83.3%+31.7%-37.6%-2.9%
GKOS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs TIVC's 18.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTIVC logoTIVCTivic Health Syst…GKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Beta (5Y)Sensitivity to S&P 5002.19x1.20x2.20x0.41x
52-Week HighHighest price in past year$5.60$146.75$20.06$76.04
52-Week LowLowest price in past year$0.74$73.16$9.82$52.81
% of 52W HighCurrent price vs 52-week peak+18.4%+91.4%+83.9%+100.0%
RSI (14)Momentum oscillator 0–10047.663.069.869.1
Avg Volume (50D)Average daily shares traded344K678K1.5M10.0M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: GKOS as "Buy", NVCR as "Buy", HOLX as "Hold". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 3.9% for HOLX (target: $79).

MetricTIVC logoTIVCTivic Health Syst…GKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHold
Price TargetConsensus 12-month target$146.67$33.50$79.00
# AnalystsCovering analysts241542
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+4.4%
Insufficient data to determine a leader in this category.
Key Takeaway

HOLX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GKOS leads in 1 (Total Returns). 1 tied.

Best OverallHologic, Inc. (HOLX)Leads 3 of 6 categories
Loading custom metrics...

TIVC vs GKOS vs NVCR vs HOLX: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is TIVC or GKOS or NVCR or HOLX a better buy right now?

For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.

3% revenue growth year-over-year, versus -33. 7% for Tivic Health Systems, Inc. (TIVC). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TIVC or GKOS or NVCR or HOLX?

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.

5%, compared to -100. 0% for Tivic Health Systems, Inc. (TIVC). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus TIVC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TIVC or GKOS or NVCR or HOLX?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

04

Which is growing faster — TIVC or GKOS or NVCR or HOLX?

By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.

3% versus -33. 7% for Tivic Health Systems, Inc. (TIVC). On earnings-per-share growth, the picture is similar: Tivic Health Systems, Inc. grew EPS 88. 9% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — TIVC or GKOS or NVCR or HOLX?

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -725. 0% for Tivic Health Systems, Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -725. 8% for TIVC. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is TIVC or GKOS or NVCR or HOLX more undervalued right now?

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

07

Which pays a better dividend — TIVC or GKOS or NVCR or HOLX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is TIVC or GKOS or NVCR or HOLX better for a retirement portfolio?

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Tivic Health Systems, Inc. (TIVC) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, TIVC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between TIVC and GKOS and NVCR and HOLX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TIVC is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

TIVC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
Run This Screen
Stocks Like

GKOS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 20%
  • Gross Margin > 46%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform TIVC and GKOS and NVCR and HOLX on the metrics below

Revenue Growth>
%
(TIVC: 15.9% · GKOS: 41.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.